¿ Affymetrix Inc., of Santa Clara, Calif., and Lexicon Genetics Inc., of The Woodlands, Texas, entered a BiotechAccess agreement giving Lexicon broad access to Affymetrix's GeneChip arrays, instrumentation and software to monitor gene expression for use in Lexicon's genomics research and development activities. Lexicon said it also will use the technology to share phenotypic and expression analysis information on new and existing targets with its collaborators.

¿ Aventis Pharma AG, of Frankfurt, Germany, and N.V. Organon, of Oss, the Netherlands, finalized agreements with Biobase GmbH, of Braunschweig, Germany, for subscriptions to the Transfac Professional database. The licenses allow all European affiliates of the companies access to the molecular biological database of gene regulation information. Financial terms were undisclosed.

¿ BioMarin Pharmaceutical Inc., of Novato, Calif., exercised its option to acquire an exclusive worldwide license to intellectual property covering Vibriolysin, an enzyme that has demonstrated efficacy related to debridement and wound healing in preclinical studies. The intellectual property includes U.S. issued patents and European issued patents, and pending patents in Canada and Japan that cover both Vibriolysin's composition of matter and use.

¿ Cambridge Drug Discovery Ltd., of Cambridge, UK, raised #7.5 million (US$11.26 million) through a private placement with existing investors to fund new chemistry capabilities. The funding also will finance the company's ion channel and kinase drug discovery research and the development of a screening platform based on retroviral display technology.

¿ Cor Therapeutics Inc., of South San Francisco, said a paper published in the Jan. 11, 2001, issue of Nature reports the cloning of a previously unidentified ADP receptor, an important mediator of platelet activation. The receptor is the target of two drugs, ticlopidine and clopidogrel.

¿ Cytoclonal Pharmaceuticals Inc., of Dallas, and Bristol-Myers Squibb Co., of New York, agreed to extend their research and development agreement for the development of new technology based on microbial fermentation for production of novel taxane therapeutics and paclitaxel. Bristol-Myers will make a $2 million payment to Cytoclonal for research support. Further financial terms were undisclosed.

¿ Enzo Biochem Inc., of Farmingdale, N.Y., said it achieved successful results in its Phase I trial of HGTV43, Enzo's HIV-1 gene medicine product. It is planning to extend the study to two additional sites and has begun the transition to Phase II.

¿ Gene Logic Inc., of Gaithersburg, Md., said it entered an agreement with Pfizer Inc., of New York, that includes a research collaboration to co-design and develop a custom GeneChip technology for mechanistic toxicology studies. Financial terms were undisclosed.

¿ Genesis Bioventures, of New York, said it acquired a significant additional equity stake in Biotherapies Inc., of Ann Arbor, Mich. An agreement effective Dec. 5 with DynaMed Inc., of Wanatchee, Wash., increased Genesis Bioventures' total equity in Biotherapies from 16.6 percent to 26.6 percent. In return for 100,000 shares of Biotherapies stock, Genesis transferred to DynaMed its interest in certain shares and warrants in IDCertify and made cash payment to DynaMed in the amount of $50,000. Genesis also issued 1.1 million shares of restricted stock to DynaMed and certain DynaMed shareholders.

¿ Genrac LLC, of Oak Ridge, Tenn., has been formed as a consortium for functional genomics research. Abgenix Inc., of Fremont, Calif., CJ America and Gene Research Access Corp. were the first members. Genrac will select functional genomics technology programs for research at Oak Ridge National Laboratory and the University of Tennessee, and will focus initially on identifying new mouse models for human genetic disease and novel methods for disease phenotype identification.

¿ Genzyme Molecular Oncology, of Framingham, Mass., entered an HIV antigen discovery and research agreement with Bruce Walker, director of the Partners AIDS Research Center at Massachusetts General Hospital. The collaboration is the first step, Genzyme said, in expanding its antigen discovery program into the infectious diseases area.

¿ IDEC Pharmaceuticals Inc., of San Diego, initiated a randomized Phase II clinical trail of IDEC-114, a primatized anti-CD80 monoclonal antibody. The placebo-controlled, multiple-dose, blinded study is designed to evaluate the clinical activity and safety of the antibody in patients with moderate-to-severe psoriasis.

¿ IGEN International Inc., of Gaithersburg, Md., filed a motion for summary judgement for one claim in its license agreement breach suit against Roche Diagnostics GmbH, a division of F. Hoffmann-La Roche Ltd., of Basel, Switzerland, in U.S. District Court for the District of Maryland. IGEN said its motion seeks a summary ruling from the court related to its allegation that Roche breached record-keeping, reporting and royalty-payment obligations under their 1992 Origen technology access agreement by taking tens of millions of dollars in "unsubstantiated 'rental surcharge' deductions."

¿ Incyte Genomics Inc., of Palo Alto, Calif., and Gene Logic Inc., of Gaithersburg, Md., reached a settlement in their patent infringement cases filed by Incyte. The settlement calls for the dismissal of all suits and gives Gene Logic a nonexclusive license to practice the technology described in the disputed patents. Incyte also licensed its microarray patent portfolio to Chiron Corp., of Emeryville, Calif., for internal use.

¿ La Jolla Pharmaceutical Co., of San Diego, said 90 percent of patients enrolled in three clinical trials had high-affinity antibodies to its lupus drug, LJP 394. La Jolla previously reported that drug-treated patients had one-third as many renal flares and less than one- half as many treatments with high-dose corticosteroids and/or cyclophosphamide as placebo-treated patients.

¿ Nymox Pharmaceutical Corp., of Maywood, N.J., said that tests conducted at the Department of Food Science at the University of Manitoba demonstrated that Nymox's novel proprietary antibacterial agent, NXC 4720, eliminated E. coli 0157:H7 in a laboratory model of a livestock gut.

¿ Pharmacopeia Inc., of Princeton, N.J., expanded its relationship with N.V. Organon, of Oss, the Netherlands, to include a new medicinal chemistry services agreement to optimize hits to lead compounds for Organon. Pharmacopeia will develop synthetic strategies and rapidly synthesize milligram quantities of a number of chemical analogues around a lead compound identified by Organon. Financial terms were undisclosed.

¿ Prodigene Inc., of College Station, Texas, named Anthony Laos president and CEO. Laos is the former group vice president of agri-products at Northrup King, of Golden Valley, Minn.

¿ SYN X Pharma Inc., of Toronto, and Janssen Research Foundation, a division of Johnson & Johnson, entered a research collaboration to test SYN X's human stroke markers in Janssen's animal models for stroke and traumatic brain injury. Under the terms, Janssen will make research payments and will purchase products from SYN X for research purposes.

¿ Union Biometrica Inc., of Somerville, Mass., licensed rights to its COPAS Technology Platform for automated drug testing in model organisms to Clontech Laboratories Inc., of Palo Alto, Calif. Financial details were unavailable.